Abstract: Objective: To evaluate the efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis (AD) in children in the real world. Methods: The data of pediatric patients with moderate-to-severe AD treated with dupilumab from November 2020 to March 2022 were collected, and changes in SCORAD, EASI, and pruritic NRS scores before and at weeks 4, 12, and 16 during treatment were compared, and adverse effects during treatment were recorded. Results: A total of 15 patients were enrolled in this study. The results showed that compared with baseline, SCORAD scores decreased by 43.4%, 63.3%, and 72.6%at weeks 4, 12, and 16 post-treatment, respectively. EASI scores decreased by 52.8%, 73.2%, 86.7%. Pruritus NRS scores decreased by 52.8%, 72.2%, 83.8%. At week 12 follow-up, 50.0% of patients had achieved EASI-75 and 10.0% had achieved EASI-90. At week 16, the percentage of patients achieving both metrics increased to 75.0% and 50.0%. No adverse reactions or serious adverse events were observed in all patients during the follow-up period. Conclusion: Dupilumab has good efficacy and a high safety profile in children with moderate-to-severe atopic dermatitis.

Key words: dupilumab, atopic dermatitis, children, real world